| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Trillium Therapeutics Inc. (“Trillium” or the “Company”) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present data on its novel CD47 checkpoint inhibitor, TTI-622, at the Developmental Therapeutics Session of the ASCO20 Virtual Scientific Program to be held May 29-31, 2020. The presentation will highlight a first-in-human study evaluating TTI-622 in patients with advanced relapsed or refractory lymphoma.
Presentation details are as follows:
Presenter: Krish Patel, MD
Title: Ongoing, First-in-human, Phase 1 Dose Escalation Study of the Investigational CD47-blocker TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma
Session: Developmental Therapeutics - Immunotherapy
Abstract: 3030
Session Type: Poster Presentation (Poster #94)
The poster will be available on the meeting website beginning Friday, May 29 at 8:00 am ET. A copy of the poster will also be available on the Events and Presentations page of Trillium’s website.
